Genome-wide Association Study to Predict Treatment Response for Molecular Targeted Therapy in Hepatocellular Carcinoma and Renal Cell Carcinoma
N/A
N/A
N/A
N/A
N/A
Open (Enrolling)
Both
Hepatocellular Carcinoma, Renal Cell Carcinoma
Both
Hepatocellular Carcinoma, Renal Cell Carcinoma
Trial Information
Genome-wide Association Study to Predict Treatment Response for Molecular Targeted Therapy in Hepatocellular Carcinoma and Renal Cell Carcinoma
Inclusion Criteria:
- All Hepatocellular carcinoma and Renal cell carcinoma patients who receive molecular
targeted therapy will be candidates for the study
Type of Study:
Observational
Study Design:
Observational Model: Cohort, Time Perspective: Retrospective
Outcome Measure:
Genotypes
Outcome Description:
To define genotypes of HCC and RCC patients who will likely to response to molecular targeted therapy. To define genotypes associated with adverse events from molecular targeted. To identify genotypes which will predict survival or disease-free survival following molecular targeted therapy.
Outcome Time Frame:
36months
Safety Issue:
No
Authority:
Korea: Food and Drug Administration
Study ID:
2008-06-050
NCT ID:
NCT01482520
Start Date:
August 2008
Completion Date:
Related Keywords:
- Hepatocellular Carcinoma
- Renal Cell Carcinoma
- Carcinoma
- Carcinoma, Renal Cell
- Carcinoma, Hepatocellular
Name | Location |
|---|
